GDC 0310

Drug Profile

GDC 0310

Alternative Names: GDC-0310; RG 6029

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Genentech; Xenon Pharmaceuticals
  • Class Analgesics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 07 Nov 2017 Genentech announces that based on results from its preclinical toxicology studies GDC 0310 will not enter a phase II clinical trial in the first quarter of 2018
  • 01 Jun 2016 Genentech completes a phase I trial in health voluneers in USA (NCT02742779)
  • 15 Mar 2016 Xenon Pharmaceuticals and Genentech extends its agreement to co-develop GDC 0310 for Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top